Press Release
Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy
–News Direct–
Disseminated on behalf of CERo Therapeutics Holdings, Inc.
Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new lease on life.
The first CAR T-cell therapy was only approved in 2017, but its already having a significant impact in the cancer treatment market. The latest success story comes from Sandra Hajlo, who just became the first person in Manitoba to be declared cancer-free following CAR T-cell therapy.1
Initially diagnosed with stage four B-cell lymphoma in 2015, Hajlo underwent successful chemotherapy. However, eight years later, her cancer returned, leading to another battle with the disease. After a misdiagnosis of scoliosis, a CT scan revealed her cancer had come back.
Her oncologist recommended CAR T-cell therapy, a new treatment where T-cells are modified to target cancer cells, making her the first recipient of this therapy at CancerCare Manitoba.
Dr. David Szwajcer, Manitoba Blood & Marrow Transplant Director at CancerCare Manitoba, explained that the CAR T-cells are collected, sent to a U.S. facility for modification, and then reintroduced to the patient. Hajlo described the procedure as quick and straightforward, taking only 20 minutes.
After undergoing CAR T-cell therapy in December 2023, Hajlo learned in April 2024 that the treatment was successful, and she is cancer-free once again, expressing her gratitude for the second chance at life.
CAR T-cell therapy does not guarantee survival, with about half of the patients not responding,but it has shown promising results in many cases.
CERo Therapeutics Holdings (NASDAQ:CERO) is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics. CERo Therapeutics is unrelated to CancerCare Manitoba and had no role in the CAR T-cell therapy described above. Nevertheless, CERo Therapeutics believes that the success of the CAR T-cell therapy in Manitoba may provide an indication of the potential for its proprietary CER-T (chimeric engulfment receptor) cell therapy.
CAR-T cell treatment has a steep price tag and some potential serious side effects including secondary cancer developing2 as well as cytokine release syndrome (CRS),3 which causes your immune system to go into overdrive and is potentially life threatening. CER-T cell therapy may provide a more cost-effective alternative with fewer side effects.
CERo Advances Innovative Cancer Immunotherapy
CERo Therapeutics (NASDAQ:CERO) developed CER-T cells to enhance efficiency and reduce side effects compared to traditional therapies by leveraging the body's natural tumor-fighting mechanisms. CER-T cells achieve this through direct tumor killing and by amplifying the body's anti-tumor immune response, and additionally by presenting cancer cell fragments to other immune cells, drawing these cells to attack the tumor.
Peer-reviewed data shows that CER-T cells have at least eight anticancer functions, offering potent, durable, and low-toxicity therapeutic benefits, with the capability to completely eliminate tumors. The company has validated these findings in 10 animal experiments, including a study on Acute Myeloid Leukemia (AML) published in March 2024.
CERo Therapeutics believes CER-T cells offer greater therapeutic potential than currently approved chimeric antigen receptor (CAR-T) cell therapy, potentially targeting both hematological malignancies and solid tumors. The company plans to begin clinical trials for its lead product candidate, CER-1236, in 2024 for treating hematological malignancies.
CERo has been diligently completing pre-clinical studies and documentation necessary to initiate clinical trials after gaining approval from the FDA for its Investigational New Drug (IND) Application.
CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) has successfully completed toxicity studies for CER-1236, a critical step before applying to the FDA for approval to begin human trials. With these studies showing that CER-1236 can be safely administered, the company is now focusing on ensuring safe manufacturing and finalizing its FDA application. Upon FDA acceptance, the company would be able to commence Phase 1 clinical trials, marking the start of the journey toward US approval and addressing unmet medical needs.
CERo plans to update shareholders on their progress, including presentations at investor conferences, potential growth of their intellectual property portfolio, and advancements in other programs beyond AML.
Click here for more information CERo Therapeutics Holdings, Inc., (NASDAQ:CERO).
Footnotes:
[1] https://globalnews.ca/news/10428035/manitobas-first-car-t-cell-therapy-patient-declared-cancer-free/
[2] https://jamanetwork.com/journals/jama/article-abstract/2815500
[3] https://www.pennmedicine.org/cancer/navigating-cancer-care/treatment-types/immunotherapy/what-is-car-t-therapy
Disclosure:
1) The author of the Article, or members of the authors immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.
2) The Article was issued on behalf of and sponsored by, CERo Therapeutics Holdings, Inc. Market Jar Media Inc. was paid $1,500 USD for the production and publishing of this article by CERo Therapeutics Holdings, Inc.s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.s engagement by CERo Therapeutics Holdings, Inc.s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-cero.
3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.
4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com.
5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.
6) This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, strive, would and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERos management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERos filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERos filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of CERo Therapeutics Holdings, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of CERo Therapeutics Holdings, Inc. or such entities and are not necessarily indicative of future performance of CERo Therapeutics Holdings, Inc. or such entities.
8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.
Contact Details
James Young
+1 800-340-9767
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/manitoba-woman-beats-stage-4-cancer-with-breakthrough-car-t-cell-therapy-472550199
MarketJar
COMTEX_453434643/2655/2024-06-06T08:32:55
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
The World’s Best Magazine Releases Issue 16 – October 2026 Edition, Excellence in Action
Australia, 10th Oct 2026, Grand Newswire –
The World’s Best Magazine has released Issue 16, the October 2026 edition, under the theme Excellence in Action: Where Knowledge, Leadership and Human Potential Shape a Better Future.
The edition examines leadership, education, wellness, health and human performance, focusing on how knowledge is applied, how learning approaches evolve and how innovation informs professional practice.
Four cover stories address these subjects. Future-Shaping Excellence examines how approaches to excellence respond to changing circumstances and emerging opportunities. Leaders Turn Expertise Into Action considers the application of professional knowledge in leadership and decision-making.
Rethinking How We Learn explores approaches to learning and the role of adaptation in education and development. On Wellness, Health & Human Performance: Ethical and Effective Innovations examines innovation in health and human performance, including the consideration of ethics and effectiveness.
Across its cover stories and interviews, Issue 16 considers how knowledge, experience and learning inform decisions and practices across different fields. The edition brings these subjects together under the theme of applying expertise and developing human capabilities.
The October 2026 edition forms part of The World’s Best Magazine’s coverage of people, ideas and work across professional and creative fields. More details about this announcement can be found via the website of The World’s Best Magazine.
About The World’s Best Magazine
The World’s Best Magazine is a publication featuring interviews, articles and cover stories about people, ideas, work and developments across a range of fields. Its editorial coverage includes leadership, education, business, health, creativity and human potential. The magazine publishes editions that examine the experiences, practices and ideas shaping professional and creative activities.
Media Contact
Organization: The World’s Best Magazine
Contact
Person: The World’s Best Magazine
Email:
info@theworldsbestmagazine.com
Country:Australia
The post The World’s Best Magazine Releases Issue 16 – October 2026 Edition, Excellence in Action
appeared first on Grand Newswire.
It is provided by a third-party content provider. Grand Newswire makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Malmö Project Outlines Business Proposal Development and Project Funds Management Activities in the Netherlands
Netherlands, 10th Oct 2026 — The Malmö Project, presented by Audrius Razma under the Project Funds Manager designation at Ossendrecht Contract, outlines an approach to business project proposal development, investment-related research, and the coordination of professional support services. The initiative is documented on the project’s online platform, where readers can explore its stated objectives and the resources associated with its activities.
The project information is published on the website of Audrius Razma and references Malmö as the focus of its business proposal activities. It describes the use of publicly available company information to develop commercial project proposals that may be presented to businesses for consideration and potential financing.
Business Research and Project Proposal Development
A central element of the Malmö Project is the preparation of business proposals informed by company information. The published material encourages readers to examine lists of businesses identified as potential investment opportunities and use relevant information to develop structured project proposals.
Business proposal development typically involves understanding a company’s activities, identifying potential commercial opportunities, assessing resource requirements, and presenting a clear rationale for a proposed initiative. A well-organized proposal can help prospective business partners evaluate the purpose, feasibility, and expected costs of a project before deciding whether to participate.
The project’s stated approach places emphasis on commercial awareness and the preparation of written material based on available business information. Such work requires careful research, transparent assumptions, and clear documentation of any projected financial outcomes.
Companies and individuals considering a proposal should independently verify the information used, assess the associated risks, and establish the terms of any potential funding arrangement before making financial commitments.
The Role of Project Funds Management
Audrius Razma is identified in the published material as the Project Funds Manager associated with Ossendrecht Contract. The role provides an administrative framework for the project’s discussion of funding proposals, portfolio documentation, and financial coordination.
Project funds management generally involves organizing financial records, documenting proposed allocations, monitoring project-related expenditures, and maintaining information that supports financial reviews. These activities can help stakeholders understand how a project is structured and what resources may be required for its implementation.
Clear documentation is particularly important when proposals involve multiple companies, external service providers, or prospective funding partners. Written agreements, verifiable records, and clearly defined responsibilities can help establish expectations and support informed decision-making.
Professional Support and Documentation
The online material also references professional services relating to legal assessments, translation, accounting reviews, investigative research, and the preparation of supporting reports. These services are presented as potential resources for individuals seeking assistance with complex administrative, financial, or legal matters.
Depending on the circumstances, professional support may help individuals organize documents, understand procedural requirements, review financial information, or prepare materials for consultation with qualified advisers.
Legal matters involving compensation claims, business liabilities, insolvency, or disputes with public authorities require an assessment of the relevant facts and applicable law. Outcomes depend on the evidence, jurisdiction, and individual circumstances. Individuals should therefore seek advice from appropriately qualified professionals before relying on potential compensation estimates or pursuing legal action.
Similarly, investment proposals should be reviewed carefully, with attention to the identity of the parties involved, the source and availability of funds, the proposed terms, and any associated risks.
Accessing Information About the Malmö Project
The project page provides the primary reference for readers interested in reviewing the Malmö Project’s published information. It outlines the proposal-development concept and identifies the associated project-management contact.
The initiative is presented in the context of business research, funding-related documentation, and coordination with professional service providers. Its practical application will depend on the details of individual proposals, the reliability of supporting information, and the terms agreed upon by the relevant parties.
Readers can consult the published page to learn more about the project’s stated approach and determine whether further clarification is required before entering into any business or financial arrangement.
Project Contact Information
Project: Malmö Project
Position: Project Funds Manager
Organization: Ossendrecht Contract Hiroshima Office Press Dansk Systems Syndikat Inc Roosendaal Journaal
Contact Person: Audrius Razma
Email: razmaaudrius@yahoo.com
Country: Netherlands
Website: https://tomashelpiai.blogspot.com/2026/08/niet-40.html
Media Contact
Organization: Ossendrecht Contract Hiroshima Office Press Dansk Systems Syndikat Inc Roosendaal Journaal
Contact Person: Audrius Razma
Website: https://tomashelpiai.blogspot.com/2026/08/niet-40.html
Email: Send Email
Country: Netherlands
Release id: 49837
View source version on King Newswire:
Malmö Project Outlines Business Proposal Development and Project Funds Management Activities in the Netherlands
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Lovering & Partners adds AI role-play for leadership, sales and influence skills with LeaderCoreAI
The Bucharest performance consultancy becomes an authorised LeaderCoreAI partner and reseller for Romania and Central and Eastern Europe
Romania, 10th Oct 2026 – Lovering & Partners, the Bucharest-based business, sales and people performance consultancy, now offers AI role-play for leadership, sales and influence skills through a partnership with Blue Horizon Training, the maker and owner of LeaderCoreAI. Lovering & Partners becomes an authorised LeaderCoreAI partner and reseller for Romania and the wider Central and Eastern Europe (CEE) region.
AI role-play simulations for difficult conversations
LeaderCoreAI is an artificial intelligence (AI) simulation platform for leadership development. Participants hold spoken, realistic conversations with AI characters – a resistant team member, a sceptical client, a room of peer managers with competing agendas. Each session ends with scored feedback and concrete recommendations.
Lovering & Partners will embed the platform into three of its own areas of work: leadership coaching and its acceleration programme for emerging leaders and managers, consultative sales training, and its ethical influence programmes. Between workshops and coaching sessions, participants practise the conversations those programmes prepare them for. They can repeat a conversation as often as they want, at five levels of difficulty.
Why practice decides whether training sticks
Pilots train to excellence in flight simulators before they carry passengers. Managers rarely get that chance. Role-play with colleagues offers a few attempts, limited by time and by the discomfort of practising in front of people they work with. So the first real test of a new skill usually comes in a real conversation, with a real person. The partnership brings the simulator into Lovering & Partners’ programmes.
“A workshop gives people the method. It does not give them the repetitions to build new capabilities,” said Colin Lovering, Co-Founder and Managing Director of Lovering & Partners. “Every client asks us the same question: will this training build skills that stick? No trainer can honestly guarantee that. Under pressure, people fall back on old instincts unless the new behaviour has been practised until it becomes the instinct. Now our clients’ people can get that practice, as much as they need.”
“We build the practice ground,” said Frank Basinski, founder of Blue Horizon Training. “We rely on partners who know how to develop people. Colin and his team have spent years doing that work with organisations in Romania and across the region. That is why we wanted them as a partner.”
How a learner experiences an AI role-play session
For the learner, a session feels like the real conversation. They speak, and the characters answer back, disagree and react to how they are treated. Nobody is watching, so people try approaches they would perhaps not dare with a real colleague. The feedback afterwards is theirs alone: what worked, what did not, and what to try next time. Participants can practise in 42 languages, so Lovering & Partners can offer the platform to multinational clients across the region.
Availability
LeaderCoreAI is available through Lovering & Partners with immediate effect, as part of its programmes or alongside them.
About Lovering & Partners
Lovering & Partners is a business, sales and people performance consultancy based in Bucharest, Romania. The firm helps organisations achieve strategic growth in those three areas. Every engagement is tailored to the client and measured by the outcome it delivers. Lovering & Partners is a founding member of the Cialdini Institute and works in English and Romanian. It is a trading name of Achieve International S.R.L. www.loveringpartners.com
About LeaderCoreAI and Blue Horizon Training
LeaderCoreAI is an AI role-play and simulation platform for leadership, sales and influence skills, made and owned by Blue Horizon Training S.R.L. of Bucharest, Romania. Leaders practise difficult conversations with AI characters in 42 languages and receive scored feedback after every session. LeaderCoreAI is sold through authorised partners who embed it into their own development programmes. Blue Horizon Training has designed and run leadership development programmes since 2020. leadercore.ai
Press contacts
Media Contact
Organization: Blue Horizon Training SRL.
Contact Person: Frank Basinski
Website: https://leadercore.ai
Email: Send Email
Country: Romania
Release id: 49826
View source version on King Newswire:
Lovering & Partners adds AI role-play for leadership, sales and influence skills with LeaderCoreAI
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
The World’s Best Magazine Releases Issue 16 – October 2026 Edition, Excellence in Action
Malmö Project Outlines Business Proposal Development and Project Funds Management Activities in the Netherlands
Lovering & Partners adds AI role-play for leadership, sales and influence skills with LeaderCoreAI
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release1 week ago
WHY VANESSA HUDGENS CHOSE AMAZON’S EKOUAER OVER LUXURY LABELS — AND WHAT IT REVEALS ABOUT FASHION’S NEW ERA
-
Press Release7 days ago
Carziqo Launches ER-SX Operations in Dallas, Introduces CARBON POINTS Rewards During Future Mobility Festival
-
Press Release1 week ago
Carziqo Brings A-DS Autonomous Delivery to San Francisco During Future Mobility Festival
-
Press Release5 days ago
EKOUAER CELEBRATES 11TH ANNIVERSARY WITH BRAND FRIEND VANESSA HUDGENS: UNVEILING “MY COMFORT ERA” THIS OCTOBER
-
Press Release3 days ago
XM Receives “Global Customer Experience Leader Award 2026” at the TrustFinance Performance Awards
-
Press Release1 week ago
Brian Baldari on the Difference Between a Mentor and a Sponsor, and Why It Decides Promotions
-
Press Release1 week ago
How to Know When to Step Back and When to Double Down in eCommerce, According to Shelton Powell
-
Press Release1 week ago
Timothy Caraboolad Publishes a Buyer’s Checklist for New-Build Condos in South Florida